1[1]Baldwin GS. The role of gastrin and cholecystokinin in normal and neoplastic gastrointestinal growth. J Gastroenterol Hepatol, 1995,10:215.
2[2]Ito S, Varro A, Dockray CJ, et al. Synergistic interaction between hypergastrinemia and helicobacter infection in a mouse model of gastric cancer. Gastroenterol, 2000, 118: ( 1 ) 36.
3[3]Smith AM, Watson SA. Review article: gastrin and colorectal cancer. Aliment Pharmacol Ther, 2000,14(10): 1231.
4[4]Sobhami TI, Dickinson CJ. Relationship of gastrin processing to colon can cer. Gastroenterol, 1995,109(4): 1384.
5[5]Watson SA, Smith AM. Hypergastrinemia promotes adenoma progerssion inthe APC( Min - / + ) mouse model of familial adenomatous polyposis. Can cer Res,2001,61(2) :625.
6[6]Fireman Z,Trost L, Kopelman Y,et al. Helicobacter pylori: seroprevalence and colorecatal cancer. Isr Med Assoc J, 2002,2(1):6.
7[7]Osbuch M, Venzon DJ, Lubensky IA, et al. Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-E1 lison syndrome. Dig Dis Sci, 1996,41(3) :604.
8[8]Smith AM, WatsonSA. Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence. Cut, 2000,47(6): 820.
9[9]Koh TJ, Dockray GJ, Varro A, et al. Overexpression of glycine-extended gas trin in transgenic mice results in increased colonic proliferation. J Clin In vest, 1999,103(8): 1119.
10[10]Singh P, Velasco M, Given R, et al. Mice overexpressing progastrin are predisposed for deveoping aberrant colonic crypt foci in response to AOM.Am J Physiol Gastrointest Liver Physiol,2000,278(3) :G390.
6[2]Smith AM, Justin T, Michaeli D, et al. Phase Ⅰ/Ⅱ study of G17-DT,an anti-gastrin immunogen, in advanced colorectal cancer. Clin Cancer Res, 2000, 6(12): 4719.
7[3]Baldwin GS. The role of gastrin and cholecystokinin in normal and neoplasticgastrointestinal growth. J Gastroenterol Hepatol, 1995, 10(2): 215.
8[5]Harrison JD, Jones JA, Morris JE. The effect of the gastrin receptor antagonist proglumide on survival in gastric carcinoma. Cancer, 1990, 66(7):1449.
9[6]Kameyama M, Nakamori S, Imaoks S, et al. Adjuvant chemo-endocrine chemotherapy with gastrin antagonist after resection of liver metastasis in colorectal cancer. Gan to Kagakn Ryoho, 1994,21:2164.
10[8]Abbruzzese JL, Gholson CF, Daugherty K, et al. A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patient with advanced pancreatic cancer. Pancreas, 1992,7:165.
